Delivery Order SPE2DB22D3004-SPE2DB25FSA45
Award Date 8/15/25
Potential Completion Date 9/8/25
Potential Value $1.8K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $34,576.32 delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes, with a completion date of August 22, 2025. This is a firm fixed price, non-set-aside contract awarded on August 1, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a biologic medication used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, representing a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,203.40 for XOLAIR 150 mg/ml syringes under a firm fixed price contract on August 8, 2025, with an ultimate completion date of August 29, 2025. This is a competitive award with no set-aside designation, and performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used to treat moderate-to-severe allergic asthma and chronic...
- The Defense Logistics Agency awarded a delivery order valued at $5,762.72 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used to treat moderate to severe allergic asthma and other allergic...
- The Defense Logistics Agency awarded a delivery order valued at $1,440.70 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on August 4, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, non-set-aside contract employs firm fixed price terms and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used in the treatment of moderate-to-severe allergic asthma and...
- The Defense Logistics Agency awarded a delivery order valued at $3,601.70 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes. This competitively awarded, firm fixed-price contract was issued on July 23, 2025, with an ultimate completion date of August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. XOLAIR (omalizumab) is a monoclonal antibody...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,464.38 for Xolair 300 mg/2 mL syringes on August 1, 2025, with an ultimate completion date of August 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody used primarily for treating moderate-to-severe allergic...
- The Defense Logistics Agency awarded a delivery order valued at $10,393.14 to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL syringes on July 22, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by August 12, 2025, with performance occurring at the vendor's location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody therapeutic used in the treatment of moderate-to-severe asthma and other allergic conditions, representing a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order for XOLAIR 150 mg/ml syringes valued at $108,051.00 under a firm fixed-price contract. This non-set-aside award was issued on July 31, 2025, with an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. XOLAIR is a biologic medication used to treat moderate-to-severe allergic asthma and other...
- This delivery order, awarded July 28, 2025, to AmerisourceBergen Drug Corp represents a competitively awarded, non-set-aside contract for the procurement of XOLAIR 150MG/ML syringes with a ceiling value of $2,161.05. The contract is funded by the Defense Logistics Agency's Medical Supply Chain and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 18, 2025. XOLAIR (omalizumab) is a monoclonal antibody...
- The Defense Logistics Agency awarded a delivery order valued at $3,464.38 to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL syringes (2 mL quantity) with an ultimate completion date of August 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued on August 1, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody used to treat moderate-to-severe asthma and other...